140 related articles for article (PubMed ID: 37917641)
21. PRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and Ca
Sengupta S; West KO; Sanghvi S; Laliotis G; Agosto LM; Lynch KW; Tsichlis PN; Singh H; Patrick KL; Guerau-de-Arellano M
Immunohorizons; 2021 Oct; 5(10):884-897. PubMed ID: 34716181
[TBL] [Abstract][Full Text] [Related]
22. The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.
Rengasamy M; Zhang F; Vashisht A; Song WM; Aguilo F; Sun Y; Li S; Zhang W; Zhang B; Wohlschlegel JA; Walsh MJ
Nucleic Acids Res; 2017 Nov; 45(19):11106-11120. PubMed ID: 28977470
[TBL] [Abstract][Full Text] [Related]
23. Getting under the skin: The role of CDK4/6 in melanomas.
Guo L; Qi J; Wang H; Jiang X; Liu Y
Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
[TBL] [Abstract][Full Text] [Related]
24. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery.
Bezzi M; Teo SX; Muller J; Mok WC; Sahu SK; Vardy LA; Bonday ZQ; Guccione E
Genes Dev; 2013 Sep; 27(17):1903-16. PubMed ID: 24013503
[TBL] [Abstract][Full Text] [Related]
25. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Vilgelm AE; Saleh N; Shattuck-Brandt R; Riemenschneider K; Slesur L; Chen SC; Johnson CA; Yang J; Blevins A; Yan C; Johnson DB; Al-Rohil RN; Halilovic E; Kauffmann RM; Kelley M; Ayers GD; Richmond A
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413145
[TBL] [Abstract][Full Text] [Related]
26. PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells.
Tan DQ; Li Y; Yang C; Li J; Tan SH; Chin DWL; Nakamura-Ishizu A; Yang H; Suda T
Cell Rep; 2019 Feb; 26(9):2316-2328.e6. PubMed ID: 30811983
[TBL] [Abstract][Full Text] [Related]
27. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
28. CDK4/6 inhibition in cancer: the cell cycle splicing connection.
Sheppard KE; AbuHammad S
Mol Cell Oncol; 2019; 6(6):e1673643. PubMed ID: 31692881
[TBL] [Abstract][Full Text] [Related]
29. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.
Li Y; Chitnis N; Nakagawa H; Kita Y; Natsugoe S; Yang Y; Li Z; Wasik M; Klein-Szanto AJ; Rustgi AK; Diehl JA
Cancer Discov; 2015 Mar; 5(3):288-303. PubMed ID: 25582697
[TBL] [Abstract][Full Text] [Related]
30. Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Wei TY; Juan CC; Hisa JY; Su LJ; Lee YC; Chou HY; Chen JM; Wu YC; Chiu SC; Hsu CP; Liu KL; Yu CT
Cancer Sci; 2012 Sep; 103(9):1640-50. PubMed ID: 22726390
[TBL] [Abstract][Full Text] [Related]
31. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
33. Unique Features of Human Protein Arginine Methyltransferase 9 (PRMT9) and Its Substrate RNA Splicing Factor SF3B2.
Hadjikyriacou A; Yang Y; Espejo A; Bedford MT; Clarke SG
J Biol Chem; 2015 Jul; 290(27):16723-43. PubMed ID: 25979344
[TBL] [Abstract][Full Text] [Related]
34. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
35. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
36. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
37. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
38. Human sulfatase 1 exerts anti-tumor activity by inhibiting the AKT/ CDK4 signaling pathway in melanoma.
Lou X; Sun B; Song J; Wang Y; Jiang J; Xu Y; Ren Z; Su C
Oncotarget; 2016 Dec; 7(51):84486-84495. PubMed ID: 27806323
[TBL] [Abstract][Full Text] [Related]
39. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
40. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Yuan Y; Nie H
Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
